CytoMed Therapeutics Ltd — Form SCHEDULE 13D/A
Filed October 16, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 18/100
What the filing says
A Schedule 13D/A (amended beneficial ownership statement) was filed on October 16, 2026 by Choo Chee Kong regarding CytoMed Therapeutics Ltd, a Singapore-incorporated pharmaceutical company (SIC 2834). The filing document itself contains no substantive disclosures of share counts, dollar amounts, percentages, dates of transactions, or specific changes to beneficial ownership—only administrative header information and filing metadata are visible in the provided text.
Why this rating
No material transaction details disclosed; routine amendment filing. Company scale and ownership change magnitude cannot be assessed from text provided.
See more from October 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.